An observational study of matrix metalloproteinase (MMP)-9 in cystic fibrosis

Graham Devereux (Lead / Corresponding author), Sandra Steele, Timothy Jagelman, Shona Fielding, Robert Muirhead, Jeff Brady, Christal Grierson, Richard Brooker, John Winter, Tom Fardon, Jonathan McCormick, Jeffrey T.J. Huang, Douglas Miller

Research output: Contribution to journalArticlepeer-review

37 Citations (Scopus)


Background: In cystic fibrosis (CF), cross-sectional studies have reported sputum matrix metalloproteinase (MMP)-9 to be elevated and negatively correlated with FEV1. This longitudinal study examined the association between MMP-9 and tissue inhibitors of metalloproteinases (TIMPs) to prognostic parameters in CF.

Method: A cross-sectional survey of CF and control subjects; CF patients were followed up for a median of 49. months. MMP-9 and TIMP-1 and TIMP-2 were quantified in sputum and plasma.

Results: Seventy-three patients with CF, median age 22 years, and 40 controls were recruited. Fifty-three of these CF patients were followed up. Prospectively, in CF subjects, plasma MMP-9 activity was adversely associated with FEV1 (β -1.15 (95% CI -2.10, -0.20), p=0.019) and rate of FEV1 decline, and plasma TIMP-1 was adversely associated with mortality: hazard ratio 3.66 (1.91-7.04), p<0.001.

Conclusions: These associations further justify investigation of MMP-9 and TIMP-1 as biomarkers for short- to medium-term FEV1 decline and mortality in patients with CF.

Original languageEnglish
Pages (from-to)557-563
Number of pages7
JournalJournal of Cystic Fibrosis
Issue number5
Early online date11 Feb 2014
Publication statusPublished - Sept 2014


  • Cystic fibrosis
  • FEV
  • MMP-9
  • Mortality
  • TIMP-1

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'An observational study of matrix metalloproteinase (MMP)-9 in cystic fibrosis'. Together they form a unique fingerprint.

Cite this